The global separation systems for commercial biotechnology market size was estimated at USD 12.92 billion in 2016. Driven by rising demand for novel drug molecules and cell-based therapies, commercial separation systems in the biotechnology industry are anticipated to witness significant growth in the forecast period.
Technological advancements in the field have been increasing. High throughput and accurate cell or molecule sorting techniques aid in a wide range of applications in various industries. Technologically advanced upstream bioprocessing technology enables the elimination of biohazardous by-products, reduces equipment size, and simplifies procedures.
Governments of various countries are providing financial assistance to small & medium enterprises to introduce novel technologies, in addition to developing & executing high-tech strategies for enhancement of commercial capabilities in this field. This is expected to drive industrial growth in the coming years.
Major advancements have been introduced in conventional methods, such as high-performance liquid chromatography, gas chromatography, supercritical fluid chromatography, centrifugation, and electrophoresis, for separation of large and sensitive molecules. These methods are majorly used in pharmaceutical, waste management, and food processing industries. In addition, modern methods, such as magnetic separators, are being used in commercial production of plastics, chemicals, and other industries.
Increasing demand for personalized medicines & cell-based therapies coupled with the recent global shortage of vaccines are placing new demands on this process, thus increasing the adoption of new technology-based systems for large -scale downstream bioprocessing. Pharmaceutical companies have a strong biopharmaceutical pipeline is rendering the growth of these instruments for purification of biomolecules from debris during its large production.
Industrial players are also entering into strategic partnerships with various research & academic institutions. Recently, researchers from Japan have developed a high-speed & efficient microfluidic chip device by using dual on-chip pumps. These high-speed systems can sort large cells with high viability and purity.
Conventional methods hold the largest revenue share in separation systems for the commercial biotechnology market. Huge investments by industrial entities for advancements in techniques, such as flow cytometry and membrane filtration systems, for large-scale production are among the few factors boosting growth.
However, modern methods in the field of commercial biotechnology are anticipated to witness the fastest growth. Ongoing investigations are anticipated to propel the growth of the segment and fulfill global industrial demand for the bioseparation equipment market in the near future.
The pharmaceutical industry accounts for the largest share in the purification and separation devices market. A combination of factors, such as existing universal shortage of vaccines, rising demand for biotherapies, and ongoing investigations in the field of novel drug development, are accelerating the growth of the segment.
Research organizations, in association with industrial partners, are intensively developing projects and producing lab-on-a-chip technology for industrial purposes, especially in the pharmaceutical segment. Most of the investigations are focused on advanced microfluidic devices that can separate biomolecules for various purposes, and this is projected to drive the market in the coming years.
North America dominated the market, particularly the U.S., and holds the largest revenue share in the field of large-scale separation instruments. Factors likely to be responsible for the dominance of this segment are the local presence of established market players, continuous R&D, and technological advancements in the region, along with a well-established industrial & healthcare framework.
However, Asia Pacific is expected to emerge as the fastest-growing segment due to emerging economies in the region, increased R&D expenditure in the area of bioprocessing instruments, and government support in China & India. Furthermore, rising demand for therapeutics, a worldwide shortage of vaccines, and ongoing research in the field is anticipated to fuel revenue generation in this region.
Recently, researchers from Japan have developed the microfluidic chip device by using dual on-chip pumps. Such high-speed systems can sort large cells with high viability & high purity and are expected to stimulate advances in existing separation techniques available in the market. The new separators have high rotation speed and are applicable for separating small molecules from gases & liquids in various industries such as petrochemical, bioengineering, and chemical other than the pharmaceutical sector.
In addition to this, factors such as growing industrialization in both developed and developing nations, governmental support, suitable strategic framework, continuous R&D in the field are expected to drive the market in the near future.
Major players in the market include Thermo Fisher Scientific; GE Healthcare; Agilent Technologies; Shimadzu Corporation; bioMérieux SA; Bio-Rad Laboratories, Inc.; Hitachi Koki Co., Ltd.; Merck & Co., Inc.; QIAGEN; WATERS; Sartorius; PerkinElmer, Inc.; Danaher; Miltenyi Biotec; and BD.
Currently, major players are forming strategic partnerships with other entities and collaborating to enhance their product portfolios in the field of separation systems to develop technologically advanced downstream processing systems.
The base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million & CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, China, India, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at the regional & country level and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this report, Grand View Research has segmented the separation systems for commercial biotechnology market on the basis of methods, application, and regions:
Method Outlook (Revenue, USD Million; 2014 - 2025)
Application Outlook (Revenue, USD Million; 2014 - 2025)
Human Blood Plasma Fractionation
Mammalian Cell Cultures
Food & Cosmetics
Regional Outlook (Revenue, USD Million; 2014 - 2025)
The Middle East and Africa (MEA)
b. The global separation systems for commercial biotechnology market size was estimated at USD 19.02 billion in 2019 and is expected to reach USD 21.57 billion in 2020.
b. The global separation systems for commercial biotechnology market is expected to grow at a compound annual growth rate of 12.9% from 2020 to 2025 to reach USD 39.47 billion by 2025.
b. North America dominated the separation systems for commercial biotechnology market with a share of 31.7% in 2019 owing to the well-established biotechnology industry in the U.S. and presence of a substantial number of biotechnology-focused companies in the region.
b. Some key players operating in the separation systems for commercial biotechnology market include Thermo Fisher Scientific; GE Healthcare; Agilent Technologies; Shimadzu Corporation; bioMérieux SA; Bio-Rad Laboratories, Inc.; Hitachi Koki Co., Ltd.; Merck & Co., Inc.; QIAGEN; WATERS; Sartorius; PerkinElmer, Inc.; Danaher; Miltenyi Biotec; and BD
b. Key factors that are driving the market growth include expansion of biopharmaceuticals pipeline programs, rising global financing for biotechnology research programs, and entry of new players in the space.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.